Intuitive Surgical, Inc. $ISRG Stock Holdings Lowered by Haven Capital Group Inc.

Haven Capital Group Inc. lessened its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 26.3% during the fourth quarter, Holdings Channel reports. The fund owned 4,564 shares of the medical equipment provider’s stock after selling 1,629 shares during the quarter. Intuitive Surgical comprises approximately 2.4% of Haven Capital Group Inc.’s investment portfolio, making the stock its 13th largest position. Haven Capital Group Inc.’s holdings in Intuitive Surgical were worth $2,585,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Centennial Wealth Advisory LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter worth approximately $226,000. Centurion Wealth Management LLC increased its position in Intuitive Surgical by 10.0% in the 4th quarter. Centurion Wealth Management LLC now owns 1,174 shares of the medical equipment provider’s stock valued at $665,000 after acquiring an additional 107 shares during the period. ORG Partners LLC raised its stake in Intuitive Surgical by 16.1% during the 4th quarter. ORG Partners LLC now owns 441 shares of the medical equipment provider’s stock valued at $250,000 after acquiring an additional 61 shares in the last quarter. ORG Wealth Partners LLC raised its stake in Intuitive Surgical by 1,222.0% during the 4th quarter. ORG Wealth Partners LLC now owns 661 shares of the medical equipment provider’s stock valued at $374,000 after acquiring an additional 611 shares in the last quarter. Finally, Embree Financial Group boosted its position in Intuitive Surgical by 28.2% during the 4th quarter. Embree Financial Group now owns 600 shares of the medical equipment provider’s stock worth $340,000 after acquiring an additional 132 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Intuitive Surgical

In related news, EVP Myriam Curet sold 105 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $493.95, for a total transaction of $51,864.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Patricia L. Wadors sold 220 shares of Intuitive Surgical stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $499.71, for a total transaction of $109,936.20. The SEC filing for this sale provides additional information. Insiders sold 32,943 shares of company stock valued at $17,279,568 in the last ninety days. Company insiders own 0.60% of the company’s stock.

Wall Street Analysts Forecast Growth

ISRG has been the topic of a number of research analyst reports. Barclays set a $712.00 price target on Intuitive Surgical and gave the company an “overweight” rating in a report on Monday, January 26th. Citigroup upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and set a $590.00 target price for the company in a research report on Wednesday, March 11th. Truist Financial raised their target price on shares of Intuitive Surgical from $620.00 to $650.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Wall Street Zen downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $714.00 price objective on shares of Intuitive Surgical in a report on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus target price of $614.95.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $452.66 on Monday. The company’s 50-day moving average price is $494.50 and its two-hundred day moving average price is $513.68. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $603.88. The stock has a market cap of $160.75 billion, a PE ratio of 57.37, a price-to-earnings-growth ratio of 3.49 and a beta of 1.66.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.26. The company had revenue of $2.87 billion during the quarter, compared to analyst estimates of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The business’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.21 EPS. On average, equities analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Investment note praising ISRG’s leadership — RiverPark’s Q4 2025 investor letter underscores Intuitive’s dominant position in robotic-assisted surgery and durable growth prospects, reinforcing a long-term bullish thesis for system and consumable revenue. What Makes Intuitive Surgical (ISRG) a Clear Leader in Robotic-Assisted Surgery?
• Positive Sentiment: Bullish coverage highlighting ISRG as a top pure-play robotics name — Financial write-ups continue to label Intuitive as a leading pure-play in surgical robotics based on its installed base and recurring-revenue model, supporting investor confidence in medium-term growth. Is Intuitive Surgical Inc. (ISRG) the best pure-play robotics stock to buy now?
• Positive Sentiment: Competitive moat emphasized by former executive — A former Intuitive exec points to training and surgeon relationships as core, durable advantages that limit competition and support pricing power for systems and consumables. Intuitive Surgical stock moat lies in training, former exec says
• Neutral Sentiment: Mention in broader “cash-heavy” screeners — ISRG appears in coverage of cash-rich companies, which can be reassuring for balance-sheet stability but doesn’t materially change near-term demand or margin outlook. 2 Cash-Heavy Stocks with Solid Fundamentals and 1 Facing Headwinds
• Negative Sentiment: Market-wide geopolitical shock driving selling — Shares fell as indexes weakened on escalating U.S.–Iran tensions and related oil/uncertainty concerns; this is a macro-driven headwind that can pressure even fundamentally strong names like ISRG in the short term. Artivion, Intuitive Surgical, GE HealthCare, LeMaitre, and Globus Medical Shares Plummet, What You Need To Know
• Negative Sentiment: Small analyst EPS trim — Erste Group marginally reduced its FY2027 EPS forecast for ISRG (tiny cut), a reminder analysts are watching margin and growth cadence — the revision is small but contributes to short-term pressure when combined with macro risk. Intuitive Surgical (ISRG) — MarketBeat coverage

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.